(Q46653570)

24 December 2017

title

Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells (English)

1 reference

24 December 2017

main subject

chronic myeloid leukemia

0 references

1 reference

E Bonhoure

1

1 reference

24 December 2017

A Lauret

2

1 reference

24 December 2017

D J Barnes

3

1 reference

24 December 2017

C Martin

4

1 reference

24 December 2017

B Malavaud

5

1 reference

24 December 2017

T Kohama

6

1 reference

24 December 2017

J V Melo

7

1 reference

24 December 2017

O Cuvillier

8

1 reference

24 December 2017

publication date

10 April 2008

1 reference

24 December 2017

published in

Leukemia

1 reference

24 December 2017

volume

22

1 reference

24 December 2017

issue

5

1 reference

24 December 2017

page(s)

971-979

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1038/leu.2008.95

exact match

0 references

cites work

Chronic myeloid leukaemia as a model of disease evolution in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Imatinib spells BAD news for Bcr/abl-positive leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

An oncogenic role of sphingosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

AraC-based pharmacotherapy of chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Involvement of sphingosine in mitochondria-dependent Fas-induced apoptosis of type II Jurkat T cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.95

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.95

1 reference

24 December 2017

PubMed ID

18401414

1 reference

24 December 2017